On February 11, 2026 Niowave Inc., a U.S.-based global leader in medical radioisotope production, reported a new long-term supply agreement with Novartis to deliver Actinium-225 (Ac-225). The agreement provides Novartis with a scalable supply of this critical isotope to support its growing portfolio of radioligand therapies (RLT). RLTs use a targeting component with a radioisotope to selectively target and destroy cancer cells. Financial terms of the agreement are not being disclosed.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The long-term agreement supports Novartis’s growing portfolio of RLT programs for difficult-to-treat cancers. In turn, Niowave expects to expand production capacity, and to support that growth, intends to begin construction of a new manufacturing facility in Lansing, Michigan, in early 2026.
"Our new agreement with Novartis underscores Niowave’s leading position as a trusted global supplier of medical radioisotopes," said Mike Zamiara, Chief Executive Officer of Niowave. "Niowave’s ability to provide dependable, scalable supply of Actinium-225 will contribute to the advancement of Novartis’s targeted cancer therapies and has the potential to meaningfully transform cancer care on a global scale."
Actinium-225 is among the most promising isotopes in oncology. Its alpha particles deliver highly potent energy, enabling the precise destruction of cancer cells while minimizing damage to surrounding healthy tissue. Despite its significant potential, global supply of Ac-225 remains limited. Niowave’s proprietary superconducting linear accelerator technology and advanced radiochemistry capabilities enable the company to provide sustainable production to address this critical supply challenge.
This new supply agreement highlights both the transformative promise of radiopharmaceuticals and the importance of securing a reliable isotope supply.
Solomon Partners and PMCF acted as advisors to Niowave.
(Press release, Novartis, FEB 11, 2026, View Source [SID1234662609])